Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 26

recruiting
3 972
countries
28
conditions
2 103

1 088 trials match your criteria

C3 glomerulopathy

Recruiting

Study on Long-Term Effects of Iptacopan in Patients with C3 Glomerulopathy or Idiopathic Immune-Complex Membranoproliferative Glomerulonephritis

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Iptacopan

Crohn's disease

Recruiting

Study on the Effectiveness and Safety of Vedolizumab, Budesonide, and Prednisone for Children with Moderate to Severe Crohn's Disease

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:0–17 years
  • Substances:Budesonide

Neoplasm malignant+1

Recruiting

Study on the Safety of Encorafenib, Binimetinib, and Ribociclib for Patients with Solid Tumors

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Binimetinib

Squamous cell carcinoma of lung+2

Recruiting

Study Comparing OSE2101 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Immunotherapy Resistance

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel

Non-small cell lung cancer

Recruiting

Study of Pembrolizumab, Vibostolimab, and Chemotherapy for Patients with Newly Diagnosed Resectable Stage II-IIIB Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Myelofibrosis

Recruiting

Study on Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis and Suboptimal Response to Ruxolitinib

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Navtemadlin

Systemic lupus erythematosus

Recruiting

Study on Long-Term Safety of Cenerimod for Adults with Moderate-to-Severe Systemic Lupus Erythematosus

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Cenerimod

Plasma cell myeloma+1

Recruiting

Study of Selinexor, Dexamethasone, and Bortezomib for Patients with Refractory Multiple Myeloma

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib

Non-small cell lung cancer

Recruiting

Study of Adagrasib Alone and with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib

Indolent systemic mastocytosis

Recruiting

Study of Elenestinib for Patients with Indolent Systemic Mastocytosis

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Elenestinib Phosphate

Ependymoma

Recruiting

Study on Ependymoma Treatment in Children, Adolescents, and Young Adults Using Cisplatin, Cyclophosphamide, Etoposide, and a Drug Combination

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years
  • Substances:Cisplatin

Rhabdomyosarcoma

Recruiting

Study of drug combinations including irinotecan, ifosfamide, vincristine, dactinomycin, regorafenib and other agents for children and adults with rhabdomyosarcoma

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cyclophosphamide

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.